Study of YH004 (4-1BB Agonist Antibody) in Advanced or Metastatic Malignancy
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Rong Chen, Ph.D
Eucure (Beijing) Biopharma Co., Ltd
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Cabrini Health Limited
Malvern East, Australia
- Westmead Hospital
Sydney, Australia
- Southside Cancer Care Centre, School of Medicine, University of Wollongong
Wollongong, Australia
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 7 Dec 2021
- Primary completion
- 16 Jul 2023
- Completion
- 16 Jul 2023
- Last update posted
- 7 Sept 2023
- Registered enrollment
- 8
- Registry id
- NCT05040932
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.